Glaucoma Australia (GA) has opened the applications period for its annual ‘Quinlivan’ Research Grants program, with a funding pool of up to $200,000 this year.
The applications period closes at 5pm (AEST) 1 July 2021, with the successful recipients to be announced on World Sight Day on Thursday 14 October 2021.
The William A Quinlivan Research Fund was established in 2006 by the late Mr Marcus Quinlivan in honour of his father. Since its inception, GA has committed more than $1 million towards Australian projects aimed at improving the lives of people with glaucoma through better detection and treatment.
This year the charitable organisation will invest up to $200,000 and anticipates between one and four grants will be awarded. All projects will be completed within three years of grant allocation and seed fund grants could be used to apply for further funding with the National Health and Medical Research Council (NHMRC) or other agencies.
“We are very proud to announce applications are now open for the 2021 round of our ‘Quinlivan’ Research Grants which will continue to fund research that supports our mission to prevent sight loss by increasing early detection and improving treatment adherence.” GA CEO Ms Annie Gibbins said.
GA stated that it supported research in four domains:
- Increasing the rate and reliability of early detection of glaucoma.
- Improving the treatment and care experience.
- Improving the quality and experience of monitoring glaucoma progression.
- Providing management tools to improve the quality of life for people with glaucoma.
‘Quinlivan’ Research Grants are awarded following rigorous evaluation, based largely on the NHMRC process.
Submissions are reviewed by the GA Independent Research Panel consisting of internationally recognised experts in glaucoma research, including the fields of ophthalmology, optometry and pharmacy.
Applications can be submitted here.
More reading
Glaukos announces TGA approval of late-stage glaucoma implant
Glaucoma Australia appoints new president
Quinlivan grant goes beyond ‘how and why’ of glaucoma research
